Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Israel-based Raziel Therapeutics jointly announced the initiation of a Phase III study for RZL-012 in submental fat (SMF) reduction in China.
Drug Profile
RZL-012, an injectable lipolytic drug developed by Raziel for the reduction of unwanted submental fat or fat in other body areas in adults, was licensed to Juvestar in 2020 for the Greater China region. The compound, injected subcutaneously into submental fat tissue in 1-2 injection sessions by trained physicians, destroys fat cells, resulting in fat volume reduction and improved appearance of the injected area.-Fineline Info & Tech
Leave a Reply